NCT03331562View on ClinicalTrials.gov

A SU2C Catalyst® Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 27, 2017

Primary Completion Date

June 29, 2020

Study Completion Date

July 10, 2020

Conditions
Pancreatic CancerPancreas AdenocarcinomaAdvanced Pancreatic CancerMetastatic Pancreatic CancerMetastatic Pancreatic Adenocarcinoma
Interventions
DRUG

Pembrolizumab

pembrolizumab solution for infusion

DRUG

paricalcitol

Paricalcitol solution for injection

DRUG

placebo

normal saline solution for injection

Trial Locations (6)

53226

Froedtert Hospital and Medical College of Wisconsin, Milwaukee

66205

The University of Kansas Cancer Center, Westwood

75246

Baylor University Medical Center Charles A. Sammons Cancer Center, Dallas

85258

HonorHealth Research Institute, Scottsdale

91010

City of Hope National Medical Center, Duarte

07962

Atlantic Medical Group-Oncology Morristown Medical Center, Morristown

All Listed Sponsors
collaborator

Stand Up To Cancer

OTHER

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Translational Genomics Research Institute

OTHER

NCT03331562 - A SU2C Catalyst® Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer | Biotech Hunter | Biotech Hunter